Clinical trials: Multi-System-Atrophy
ALS, SCI - Spinal Cord Injury
ECoG BMI for Motor and Speech Control
Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.
- Conditions
- ALS, SCI - Spinal Cord Injury, Stroke, Multiple Sclerosis
- Trial name
- BRAVO (NCT03698149)
- Testing
- PMT/Blackrock Combination Device
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Karunesh Ganguly
Parkinson's Disease, Multiple System Atrophy
Analysis of the Enteric Nervous System Using Colonic Biopsies
The aim of this project is to develop an original biomarker for Parkinson's disease (PD) and other parkinsonian syndromes (multiple system atrophy and progressive supranuclear palsy) based upon the detection of pathological…
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- ColoBioParker (NCT01353183)
- Testing
- colonoscopy or rectosigmoidoscopy
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Nantes University Hospital
Optic Neuropathy, Optic Neuropathy, Ischemic
Building Research With Artificial Intelligence in Neuro-Ophthalmology
The research team, recognized as a world leader in Artificial Intelligence for neuro-ophthalmology, has shown that it is possible to diagnose certain neuro-ophthalmologic or neurologic disorders from a single retinal fundus image…
- Conditions
- Optic Neuropathy, Optic Neuropathy, Ischemic, Optic Neuritis, Optic Nerve Diseases
- Trial name
- BRAIN (NCT06390579)
- Testing
- Deep learning algorithm applied on retrospectively collected color fundus photographs
- Where
- France
- Volunteers
- 693 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Multiple Sclerosis
Sunphenon in Progressive Forms of Multiple Sclerosis
The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG) treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more effective than an oral placebo treatment…
- Trial name
- SUPREMES (NCT00799890)
- Testing
- Sunphenon EGCG
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Friedemann Paul
Multiple System Atrophy
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following randomization to continued therapy with droxidopa or…
- Trial name
- DOPS-AMS (NCT02071459)
- Testing
- L-Threo DOPS
- Where
- 13 sites in France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Toulouse
Spinal Muscular Atrophy
Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)
Spinal Muscular Atrophy (SMA) is an autosomal recessive disease caused by a mutation of exon 7, in 95% of cases, encoding the gene for the motor neuron survival protein called SMN1 (Survival Motor Neuron) located on chromosome…
- Trial name
- NUSI-AD-5qSM (NCT04576494)
- Testing
- Monthly assessments of functional motor abilities by a trained therapist, Nusinersen
- Where
- France
- Volunteers
- 4 people
- Sponsor
- CHU de Reims
Duchenne Muscular Dystrophy
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
The purpose of this study is to determine if ACE-031 is safe and well-tolerated in boys with Duchenne Muscular Dystrophy (DMD) and to select the optimal doses of ACE-031 in terms of safety and pharmacodynamic (PD) activity for…
- Trial name
- NCT01099761
- Testing
- ACE-031 0.5 mg/kg q4wk, ACE-031 1.0 mg/kg q2wk
- Where
- 5 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Leukodystrophy, White Matter Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes.
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy
- Trial name
- NCT02699190
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Children's Hospital of Philadelphia
Duchenne Muscular Dystrophy
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.
- Trial name
- NCT04768062
- Testing
- Viltolarsen
- Where
- 31 sites in Australia, Canada and 15 more
- Volunteers
- 74 people
- Sponsor
- NS Pharma, Inc.
Myotonic Dystrophy Type 1 (DM1)
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1).
- Trial name
- ACHIEVE (NCT05481879)
- Testing
- DYNE-101
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 127 people
- Sponsor
- Dyne Therapeutics
Multiple System Atrophy, Progressive Supranuclear Palsy
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus'…
- Trial name
- NCT00211224
- Testing
- Riluzole
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Multiple System Atrophy
TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System Atrophy
TRACK-MSA is an observational, non-interventional, longitudinal natural history study to define changes in clinical, neurological, blood, CSF, and neuroimaging biomarkers in patients with multiple system atrophy (MSA) comparing…
- Trial name
- NCT04450992
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
Multiple System Atrophy, Parkinson Disease
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
This is a non-interventional observational study designed to systematically record the results of routine laryngeal examinations and specific characteristics of dysphagia in patients with neurodegenerative disorders.
- Conditions
- Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy, Motor Neuron Disease
- Trial name
- FEEMSA (NCT04706234)
- Where
- 16 sites in Austria, Germany and 6 more
- Volunteers
- 350 people
- Sponsor
- Kliniken Beelitz GmbH
Atypical Parkinsonism, MSA - Multiple System Atrophy
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
This project aims to investigate whether an integrated model based on proactive and reactive telenursing monitoring coordinated by a parkinsonism nurse specialist (case manager) is able to improve care delivery and quality of…
- Conditions
- Atypical Parkinsonism, MSA - Multiple System Atrophy, PSP, Nurse-Patient Relations
- Trial name
- NCT05792332
- Testing
- Telemonitoring, Standard-of-care
- Where
- 4 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Parkinson's Disease, Multiple System Atrophy
An Observational Study of Parkinson's Disease and Other Synucleinopathies (EASE-PD)
The study is a multi-center, observational study to evaluate the feasibility of α-synuclein-related biomarkers and imaging data in the disease diagnosis and prognosis evaluation in Synucleinopathies and healthy subjects.
- Trial name
- EASE-PD (NCT05638815)
- Where
- 4 sites in China
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- SciNeuro
Spinal Cord Injuries, Multiple System Atrophy, Parkinson Variant
Transcutaneous Spinal Cord Stimulation Home Study
The goal of this pilot clinical trial is to examine the safety and feasibility of SCONE as home based therapy for orthostatic hypotension and bowel dysfunction in individuals with spinal cord injury or multiple system atrophy.
- Trial name
- NCT06838637
- Testing
- Spinal COrd NEuromodulation ("SCONE") Device
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Michael Berger
Multiple System Atrophy (MSA)
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT05086094
- Testing
- BHV3241, verdiperstat
- Where
- United States
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Relapsing-Remitting Multiple Sclerosis
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
This study is designed to evaluate the neuroprotective effect of lamotrigine in the combination of interferon beta 1a once weekly intramuscular in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT00917839
- Testing
- lamotrigine
- Where
- Switzerland
- Volunteers
- 88 people
- Sponsor
- Cantonal Hospital of St. Gallen
Multiple System Atrophy
GDNF Gene Therapy for Multiple System Atrophy
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or…
- Trial name
- NCT04680065
- Testing
- AAV2-GDNF gene therapy
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Brain Neurotherapy Bio, Inc.
Multiple System Atrophy
Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers
Multiple system atrophy (MSA) is a rare neurodegenerative disorder that leads to major disability, forcing patients and caregivers to adapt their environment and lifestyle.
- Trial name
- ETP@MS (NCT05819957)
- Testing
- Therapeutic Education Program (TEP)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse